Garth Cruickshank - Concepedia

Author

Garth Cruickshank

University of Birmingham

Also Known As

Garth Cruickshank, Garth S. Cruickshank

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

University of Birmingham Queen Elizabeth Hospital Birmingham University Hospitals Birmingham NHS Foundation Trust Cambridge University Hospitals NHS Foundation Trust Cancer Research UK

About

Garth Cruickshank is an author at University of Birmingham specializing in medicine, neuro-oncology, and high-grade gliomas.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	651
2	Health Sciences	4	4	208
3	Neurology	4	4	208
4	Engineering	1	1	129
5	Biochemistry	1	1	298

Garth Cruickshank

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors R Rampling, Garth Cruickshank, Alexander D. Lewis, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyBiochemistryMalignant DiseaseDirect MeasurementBioanalysis	1994	298
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial Catherine Hanna, Kathreena M. Kurian, Karin Williams, Neuro-Oncology	2020	139
DNA methylation profiles of long- and short-term glioblastoma survivors Thoraia Shinawi, Victoria Hill, Dietmar Krex, Epigenetics Neuro-oncologyEngineeringMedicineGeneticsDna Methylation	2013	129
<scp>l</scp>-Amino Acid Transporter-1 and Boronophenylalanine-Based Boron Neutron Capture Therapy of Human Brain Tumors A. Detta, Garth Cruickshank Cancer Research	2009	127
The intrathecal CD163‐haptoglobin–hemoglobin scavenging system in subarachnoid hemorrhage James Galea, Garth Cruickshank, Jessica L. Teeling, Journal of Neurochemistry Delayed Cerebral IschemiaSignificant Intrathecal HemolysisIntrathecal Cd163‐haptoglobin–hemoglobinCerebral Vascular RegulationNeurovascular Disease	2012	112
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2. Anthony J. Chalmers, Susan Short, Colin Watts, Journal of Clinical Oncology Parp Inhibitor CombinationsElderly GbmPharmacotherapyHigh-grade GliomasGlioma	2018	35
Results of the OPARATIC trial: A phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM). Sarah Halford, Garth Cruickshank, Laurence Dunn, Journal of Clinical Oncology Surgical OncologyOlaparib DosesRelapsed GlioblastomaPharmacotherapyHigh-grade Gliomas	2017	33
Verteporfin selectively kills hypoxic glioma cells through iron-binding and increased production of reactive oxygen species Katherine L. Eales, Edward A. Wilkinson, Garth Cruickshank, Scientific Reports	2018	31
Primary and metastatic brain tumours in adults: summary of NICE guidance Alex Bates, Eva Gonzalez-Viana, Garth Cruickshank, BMJ Tumor InnervationBrain MetastasesCancer ManagementCancer.1 SurvivalHigh-grade Gliomas	2018	28
Proliferative activity and <i>in vitro</i> replication of HSV1716 in human metastatic brain tumours A. Detta, J. Harland, Isma Hanif, The Journal of Gene Medicine	2003	26

Page 1